(Q28217605)

1

0 references

Maria Cristina Colanardi

2

0 references

Antonio Ferrannini

3

0 references

Alfredo Tursi

Annals of Allergy, Asthma & Immunology

4

0 references

language of work or name

English

0 references

publication date

January 2005

0 references

published in

0 references

volume

94

0 references

issue

1

0 references

page(s)

29-33

0 references

cites work

Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Benzydamine: an alternative nonsteroidal anti-inflammatory drug in patients with nimesulide-induced urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Floctafenine: a valid alternative in patients with adverse reactions to nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Meloxicam in hypersensitivity to NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Rofecoxib safe in NSAID hypersensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Chronic sinusitis with rofecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Rofecoxib-induced instant aquagenic wrinkling of the palms

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Fixed drug eruption to rofecoxib with cross-reactivity to sulfonamides

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Erythema multiforme due to rofecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Aseptic meningitis associated with rofecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Urticaria and angioedema induced by COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Atopy and intolerance of antimicrobial drugs increase the risk of reactions to acetaminophen and nimesulide in patients allergic to nonsteroidal anti-inflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Detection of patients with multiple drug allergy syndrome by elective tolerance tests.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021

Sensitivity to nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961281-1

7 January 2021